These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17720885

  • 1. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
    Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.
    J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
    Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I.
    Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
    [Abstract] [Full Text] [Related]

  • 4. Activity-dependent neuroprotective protein: from gene to drug candidate.
    Gozes I.
    Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064
    [Abstract] [Full Text] [Related]

  • 5. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N, Pikman R, Giladi E, Gozes I.
    Curr Pharm Des; 2011 May; 17(25):2603-12. PubMed ID: 21728979
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
    Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D.
    Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216
    [Abstract] [Full Text] [Related]

  • 8. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
    Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.
    Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
    [Abstract] [Full Text] [Related]

  • 9. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.
    Mandel S, Rechavi G, Gozes I.
    Dev Biol; 2007 Mar 15; 303(2):814-24. PubMed ID: 17222401
    [Abstract] [Full Text] [Related]

  • 10. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
    Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I.
    Peptides; 2005 Aug 15; 26(8):1520-7. PubMed ID: 16042992
    [Abstract] [Full Text] [Related]

  • 11. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
    Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.
    J Alzheimers Dis; 2014 Aug 15; 40 Suppl 1():S23-36. PubMed ID: 24503616
    [Abstract] [Full Text] [Related]

  • 12. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
    Ivashko-Pachima Y, Maor-Nof M, Gozes I.
    PLoS One; 2019 Aug 15; 14(3):e0213666. PubMed ID: 30865715
    [Abstract] [Full Text] [Related]

  • 13. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
    Gozes I.
    Peptides; 2011 Feb 15; 32(2):428-31. PubMed ID: 21050875
    [Abstract] [Full Text] [Related]

  • 14. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
    Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM.
    Curr Alzheimer Res; 2005 Apr 15; 2(2):149-53. PubMed ID: 15974912
    [Abstract] [Full Text] [Related]

  • 15. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
    Gozes I.
    Curr Pharm Des; 2011 Apr 15; 17(31):3413-7. PubMed ID: 21902667
    [Abstract] [Full Text] [Related]

  • 16. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
    Sragovich S, Malishkevich A, Piontkewitz Y, Giladi E, Touloumi O, Lagoudaki R, Grigoriadis N, Gozes I.
    Transl Psychiatry; 2019 Jan 15; 9(1):2. PubMed ID: 30664622
    [Abstract] [Full Text] [Related]

  • 17. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
    Magen I, Gozes I.
    Neuropeptides; 2013 Dec 15; 47(6):489-95. PubMed ID: 24210139
    [Abstract] [Full Text] [Related]

  • 18. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation.
    Taniguchi T, Doe N, Matsuyama S, Kitamura Y, Mori H, Saito N, Tanaka C.
    FEBS Lett; 2005 Oct 24; 579(25):5704-12. PubMed ID: 16219306
    [Abstract] [Full Text] [Related]

  • 19. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
    Jouroukhin Y, Ostritsky R, Gozes I.
    J Mol Neurosci; 2012 Nov 24; 48(3):597-602. PubMed ID: 22956189
    [Abstract] [Full Text] [Related]

  • 20. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
    Zhang Q, Zhang X, Sun A.
    Acta Neuropathol; 2009 Jun 24; 117(6):687-97. PubMed ID: 19190923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.